Four new deals filed terms Monday, as homebuilder Taylor Morrison (TMHC), UK-based shuttle tank operator KNOT Offshore Partners (KNOP) and biotechs Chimerix (CMRX) and Omthera Pharmaceuticals (OMTH) hit the calendar, bringing the total to seven deals expected to price in the beginning of April. The group joins Texas community bank Independent Bank Group (IBTX), Harvard Bioscience carve-out Harvard Apparatus Regenerative Technology (HART) and Apollo-backed transaction processor Evertec (EVTC), which were added to the calendar last week.
Homebuilder Taylor Morrison launches $500 million IPO
Taylor Morrison Home Corporation, one of America's top ten homebuilders, expects to offer 23.8 million shares at a price range of $20 to $22 to raise $500 million. At the midpoint of the proposed range, Taylor Morrison would command a market value of $2.6 billion. Oaktree Capital and TPG Capital will each maintain a 38% stake in the company after the offering. The company initially filed with a proposed offering of $250 million in December 2012 but increased the expected deal size in February after the strong performances from fellow housing plays TRI Pointe Homes (TPH, up 19%) and Boise Cascade Company (BCC, up 62%)
UK-based shuttle tanker operator KNOT Offshore Partners sets terms for US IPO
KNOT Offshore Partners LP, a recently formed LP which will own, operate and acquire shuttle tankers under long-term charters, announced that it plans to raise $149 million by offering 7.5 million shares at a price range of $19 to $21. At the midpoint of the proposed range, KNOT Offshore Partners LP would command a market value of $171 million. The company, which booked $66 million in sales for the 2012 fiscal year, initially filed confidentially on December 21, 2012 and publicly on February 28, 2013.
Biotechs Omthera Pharmaceuticals and Chimerix set terms
Omthera Pharmaceuticals, which is developing therapies for abnormalities in blood lipids, announced that it plans to raise $75 million by offering 5.8 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Omthera Pharmaceuticals would command a market value of $275 million. The company, which has yet to generate revenue, filed confidentially on January 25 and publicly on March 28.
Chimerix, which is developing oral antiviral therapeutics for CMV, announced that it hopes to raise $85 million by offering 6.1 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Chimerix would command a market value of $325 million. The company, which booked $34 million in revenue for the 2012 fiscal year, filed confidentially on January 30 and publicly on March 8.
Apollo-backed transaction processor Evertec seeking $400 million IPO
Evertec, which is a leading full-service transaction processing service in Latin America and the Caribbean, expects to raise $400 million by offering 21.1 million shares (69% insider) at a price range of $18 to $20. At the midpoint of the proposed range, Evertec would command a fully diluted market value of $1.6 billion. Apollo (35% post-IPO stake) and Popular (34%) are selling on the offering. The company, which booked $342 million in sales in the 2012 fiscal year, filed confidentially on November 2, 2012 and publicly on February 6, 2013.
Texas-based Independent Bank Group sets terms for $80 million IPO
Independent Bank Group, a Texas-based bank with 30 offices serving the Dallas-Forth Worth metropolitan area, plans to raise $80 million by offering 3.2 million shares at a price range of $24 to $26. At the midpoint of the proposed range, Independent Bank Group would command a fully diluted market value of $292 million. The company, which booked $81 million in sales 2012 fiscal year, filed confidentially on December 28, 2012 and publicly on February 27, 2013.
Harvard Bioscience spinoff files for $19 million IPO
Harvard Apparatus Regenerative Technology, a regenerative medicine company that developed a synthetic replacement trachea, expects to raise $19 million by offering 1.7 million shares at a price range of $10 to $12. At the midpoint of the proposed range, the company would command a market value of $110 million. The company, which is yet to generate revenue, originally filed with a proposed deal size of $20 million on December 12, 2012. Its parent company, Harvard Bioscience, will have a 83% stake after the offering.
